Acutaas Chemicals Ltd

ACUTAAS

Watchlist

AI Mode

‌

Market Cap

₹ 13,350 Cr

P/E

59.60

Turned 1 L into 3.60 L in last 5 Years

‌

Investment Checklist

How to read checklist?

Performance

MARKET LEADER

Valuation

OVERVALUED

Growth

EXCEPTIONAL

Profitability

HIGH MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Acutaas Chemicals Limited specializes in manufacturing Advanced Pharmaceutical Intermediates and Specialty Chemicals. It has recently focused on diversifying into battery chemicals and semiconductor chemicals as significant growth pillars.

Its revenue surged by 24.1% year-on-year in Q2 FY26, fueled by robust performance in Advanced Pharmaceutical Intermediates. The company is keen on achieving a 25% revenue growth for the full year, backed by strategic expansions.

The company is investing heavily in new verticals, notably in battery and semiconductor chemicals, with strategic partnerships and JVs in Korea marking major milestones for future growth.

Acutaas Chemicals aims for approximately 28% to 30% EBITDA margins in FY26 through improved product mix, operational efficiencies, and strategic capital investments.

Adapting to global market dynamics, Acutaas Chemicals is strategically restructuring its product portfolio to phase out low-margin products and focus on sustainable, higher-margin offerings.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

13,350 Cr

Volatility

High Risk

P/E Ratio

59.6

Industry P/E

59.2

PEG Ratio

1.7

P/B Ratio

9.4

52W High

1,901.35

52W Low

919.63

Sales CAGR

40.34%

23.92%

32.80%

10Y

—

Profit CAGR

229.34%

30.40%

42.17%

10Y

—

ROE

TTM

15.84%

10.97%

12.50%

10Y

—

ROCE

TTM

21.30%

15.38%

16.96%

10Y

—

Technicals

‌

Forecasts

No. of Analysts

12

1Y Price Target

1868.13 ▲ 11.13%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Dec 03, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
NEULANDLAB	16500.00	21,069 Cr	107.61	13.01	0.07	12.09	14.48	9.48
JUBLPHARMA	1087.90	17,322 Cr	34.85	2.63	0.46	7.25	7.77	3.51
ACUTAAS	1630.10	13,350 Cr	59.60	9.44	0.09	15.84	21.30	13.21
GUJTHEM	390.15	4,251 Cr	88.07	16.08	0.17	18.26	19.25	12.82
AARTIDRUGS	391.00	3,582 Cr	18.00	2.44	0.25	13.56	13.12	7.62
HIKAL	250.05	3,090 Cr	305.61	2.59	0.32	0.85	4.28	0.43
SMSPHARMA	323.45	3,035 Cr	35.97	4.16	0.12	11.57	12.36	6.35

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	154	172	166	225	177	247	275	308	207	306
Expenses	120	148	140	182	147	198	206	224	156	211
Operating Profit	34	25	27	43	30	49	69	85	51	95
OPM %	22.12	14.40	15.93	19.19	16.71	19.83	24.97	27.54	24.57	31.13
Other Income	1.15	-30	3.49	1.01	1.04	8.44	1.67	5.78	16	9.84
Interest	0.51	0.82	2.54	2.07	4.43	0.50	0.69	0.60	0.64	0.58
Depreciation	3.71	3.69	3.76	4.90	6.18	6.83	6.32	7.30	8.13	8.40
Profit Before Tax	31	-9.94	24	37	20	50	63	83	58	96
Tax %	28.12	-71.23	24.85	30.99	26.37	24.92	28.25	24.29	24.23	25.29
Net Profit	22	-17	18	26	15	38	45	63	44	72
EPS in Rs	2.03	-2.10	2.18	3.09	1.83	4.69	5.68	3.90	5.41	8.82

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	239	240	341	520	617	717	1,037
Expenses	196	199	260	415	494	589	784
Operating Profit	42	41	80	105	123	128	253
OPM %	17.64	17.12	23.53	20.22	19.88	17.91	24.43
Other Income	0.38	2.84	1.38	2.76	4.32	-25	32
Interest	4.75	5.59	5.62	6.41	2.41	5.94	2.43
Depreciation	2.60	3.52	4.19	10	12	16	29
Profit Before Tax	35	35	72	91	112	82	254
Tax %	33.65	20.96	24.72	21.33	25.75	40.53	25.38
Net Profit	23	27	54	72	83	49	190
EPS in Rs	—	—	—	9.25	10.38	5.19	23.81
Dividend Payout %	0.00	0.00	0.00	14.27	13.12	25.71	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	11	11	32	36	36	37
Reserves	72	101	135	486	558	637
Borrowings	48	54	137	0.84	3.60	217
Other Liabilities	83	66	110	136	169	205
Total Liabilities	213	232	413	659	767	1,096
Fixed Assets	79	85	186	205	259	427
CWIP	1.96	12	0.20	2.96	30	125
Investments	1.64	1.73	1.43	1.71	1.65	0.20
Other Assets	131	133	225	450	477	543
Total Assets	213	232	413	659	767	1,096

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	15	27	28	-12	66	125	118
Cash from Investing Activity	-21	-24	-101	-121	-33	-365	-224
Cash from Financing Activity	5.62	0.19	72	140	-12	239	261
Net Cash Flow	-0.41	3.33	-1.14	7.61	20	-0.86	156

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	May 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	39.41%	39.41%	38.93%	39.91%	39.91%	39.07%	35.98%	35.97%	35.96%	35.96%	32.66%	32.66%
FIIs	6.36%	6.73%	7.16%	11.65%	8.97%	10.01%	12.92%	13.87%	15.52%	16.48%	16.94%	16.85%
DIIs	3.63%	5.23%	5.94%	7.58%	6.81%	8.81%	14.81%	19.93%	20.25%	18.33%	22.39%	22.60%
Public	50.60%	48.63%	47.97%	40.86%	44.31%	42.12%	36.29%	30.23%	28.27%	29.23%	28.01%	27.89%
Total Shareholders	78,786	70,352	72,897	83,344	95,784	92,721	90,987	93,394	95,756	1,14,060	1,19,890	1,08,664

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Nov 24, 2025	Ishares core msci emerging ma...	Bulk	Buy	1,852.12	98.22 Cr	5,30,290	0.64
May 20, 2025	Chetankumar chhaganlal vaghasia	Insider - Promoter & Director	Disposal	1,115.00	150.40 Cr	13,48,921	1.64
May 20, 2025	Nareshkumar ramjibhai patel	Insider - Promoter & Director	Disposal	1,115.00	150.40 Cr	13,48,921	1.64
Mar 21, 2025	The vanguard group inc ac van...	Bulk	Buy	2,425.43	58.97 Cr	2,43,115	0.59
Jan 30, 2025	Graviton research capital llp	Bulk	Sell	2,342.16	49.12 Cr	2,09,716	0.51
Jan 30, 2025	Graviton research capital llp	Bulk	Buy	2,340.63	49.16 Cr	2,10,035	0.51
Jan 29, 2025	Graviton research capital llp	Bulk	Sell	2,104.95	59.90 Cr	2,84,560	0.69
Jan 29, 2025	Graviton research capital llp	Bulk	Buy	2,102.18	59.75 Cr	2,84,241	0.69
Jan 06, 2025	Ram mohan lokhande	Insider - Director	Disposal	2,130.00	0.09 Cr	400	—
Jan 06, 2025	Ram mohan lokhande	Insider - Director	Acquisition	100.00	0.02 Cr	2,000	—

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q4 FY24

Investor Presentation

Q3 FY24

Showing 1 - 8 of 18

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
NEULANDLAB	16500.00	21,069 Cr	107.61	13.01	0.07	12.09	14.48	9.48
JUBLPHARMA	1087.90	17,322 Cr	34.85	2.63	0.46	7.25	7.77	3.51
ACUTAAS	1630.10	13,350 Cr	59.60	9.44	0.09	15.84	21.30	13.21
GUJTHEM	390.15	4,251 Cr	88.07	16.08	0.17	18.26	19.25	12.82
AARTIDRUGS	391.00	3,582 Cr	18.00	2.44	0.25	13.56	13.12	7.62
HIKAL	250.05	3,090 Cr	305.61	2.59	0.32	0.85	4.28	0.43
SMSPHARMA	323.45	3,035 Cr	35.97	4.16	0.12	11.57	12.36	6.35

Overview

Detailed Summary

The company is investing heavily in new verticals, notably in battery and semiconductor chemicals, with strategic partnerships and JVs in Korea marking major milestones for future growth.

Acutaas Chemicals aims for approximately 28% to 30% EBITDA margins in FY26 through improved product mix, operational efficiencies, and strategic capital investments.

Adapting to global market dynamics, Acutaas Chemicals is strategically restructuring its product portfolio to phase out low-margin products and focus on sustainable, higher-margin offerings.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

13,350 Cr

Volatility

High Risk

P/E Ratio

59.6

Industry P/E

59.2

PEG Ratio

1.7

P/B Ratio

9.4

52W High

1,901.35

52W Low

919.63

Sales CAGR

40.34%

23.92%

32.80%

10Y

—

Profit CAGR

229.34%

30.40%

42.17%

10Y

—

ROE

TTM

15.84%

10.97%

12.50%

10Y

—

ROCE

TTM

21.30%

15.38%

16.96%

10Y

—